Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,152.00
(
0.57%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
101.19
(
2.93%
)
Bitcoin
74,642.04
(
-0.27%
)
News Focus
News Focus

Replies to post #112548 on Biotech Values

Replies to #112548 on Biotech Values
icon url

DewDiligence

01/14/11 12:48 PM

#112569 RE: DewDiligence #112548

The primary beneficiary of ABT’s mishap with Briakinumab is JNJ’s Stelara, which has been a commercial disappointment to date.